Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

@article{Holdhoff2012UseOP,
  title={Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas},
  author={M. Holdhoff and X. Ye and J. Blakeley and L. Blair and P. Burger and S. Grossman and L. Diaz},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={110},
  pages={279-285}
}
This study was conducted to assess the current pattern of use and the impact of available molecular predictive and prognostic biomarkers on clinical care in patients with glioblastoma (GBM). An online questionnaire consisting of 15 questions about the frequency of use and clinical utility of tissue-based molecular tests was distributed to 1,053 members of the Neuro-Oncology Community in the United States. A total of 320 responses (30.4 %) were collected. 73 respondents who did not see GBM… Expand
26 Citations

Figures, Tables, and Topics from this paper

Actionable molecular biomarkers in primary brain tumors.
  • 17
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
  • 226
  • PDF
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
  • 17
  • PDF
Glioblastoma – A tale of two tumors: Case comparison and literature review
  • 31
  • Highly Influenced
  • PDF
Current Standards of Care in Glioblastoma Therapy
  • 56
  • PDF
...
1
2
3
...

References

SHOWING 1-10 OF 15 REFERENCES
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
  • 1,390
Controversies in the adjuvant therapy of high-grade gliomas.
  • 42
  • PDF
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
  • D. Reardon, M. Egorin, +17 authors H. Friedman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
  • 315
IDH1 and IDH2 mutations in gliomas.
  • 2,512
  • PDF
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
  • 403
  • PDF
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
  • M. Hegi, L. Liu, +5 authors M. Gilbert
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
  • 649
  • PDF
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
  • 82
  • PDF
...
1
2
...